Pricing Log in Create free account
Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−9.42%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.28 0.29 −0.43%
Market cap
$39.0B
P/E
37.6×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Royalty Pharma PLC 10-K filed Feb 11, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 9:04 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 12, 2025: 81 added · 73 removed · 61 modified; 9 with only figures updated; 1 moved without change

215 more changes in this Item, word by word, in Powerpack.